Dynavax Technologies Co. (NASDAQ:DVAX) Holdings Boosted by Franklin Resources Inc.

Franklin Resources Inc. raised its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 5.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 82,415 shares of the biopharmaceutical company’s stock after buying an additional 4,459 shares during the quarter. Franklin Resources Inc. owned approximately 0.06% of Dynavax Technologies worth $862,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DVAX. Renaissance Technologies LLC grew its stake in shares of Dynavax Technologies by 2.2% in the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after purchasing an additional 53,600 shares in the last quarter. Great Point Partners LLC grew its position in Dynavax Technologies by 87.7% in the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after buying an additional 1,109,080 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Dynavax Technologies during the 2nd quarter worth about $17,615,000. Mizuho Markets Americas LLC boosted its stake in Dynavax Technologies by 17.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock valued at $15,369,000 after purchasing an additional 204,475 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in shares of Dynavax Technologies by 8.3% in the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after buying an additional 82,449 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Stock Down 0.2 %

Shares of Dynavax Technologies stock opened at $13.00 on Monday. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01. The stock has a 50-day moving average price of $12.45 and a 200 day moving average price of $11.54. The company has a market cap of $1.71 billion, a P/E ratio of 100.01 and a beta of 1.33.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.